Meeting
2022 ASCO Annual Meeting
Anlotinib plus tislelizumab combined with chemotherapy as neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study.
Authors
Jing Luo
Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, China
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT04914390
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS618)
DOI
10.1200/JCO.2022.40.16_suppl.TPS618
Abstract #
TPS618
Poster Bd #
383b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Pathological complete response rate and survival in patients with BRCA-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242).
First Author: Lisa Katharina Katharina Richters
Poster
2018 ASCO Annual Meeting
Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).
First Author: Lajos Pusztai
Poster
2017 ASCO Annual Meeting
Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.
First Author: Peter Schmid
Poster
2017 ASCO Annual Meeting
A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).
First Author: Sibylle Loibl